Vasomotor Symptoms Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals by DelveInsight | Mithra Pharmaceuticals, Bayer, Nerre Therapeutics, Astellas Pharma, MenoGeniX

Posted on
by

Vasomotor Symptoms Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals by DelveInsight | Mithra Pharmaceuticals, Bayer, Nerre Therapeutics, Astellas Pharma, MenoGeniX
DelveInsight’s “Vasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Vasomotor Symptoms.

DelveInsight’s “Vasomotor Symptoms Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Vasomotor Symptoms, historical and forecasted epidemiology as well as the Vasomotor Symptoms market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Vasomotor Symptoms market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vasomotor Symptoms Market Forecast

 

Some of the key facts of the Vasomotor Symptoms Market Report: 

  • The Vasomotor Symptoms market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Up to 75% of American women experience hot flashes around menopause, according to the North American Menopause Society. Hot flashes often happen over a period of between six months and two years, although they can persist up to ten years
  • Vasomotor Symptoms were widespread in 136,057,000 cases across the 7MM in 2022, and they may decline somewhat at a moderate CAGR through 2032. Vasomotor symptoms were most frequently reported in the 7MM population in the United States
  • The projected number of cases with Vasomotor Symptoms in EU4 and the UK in 2022 was 59,536,000. This number is expected to decline by the year 2032 at a modest CAGR. Germany had the most common cases of vasomotor symptoms in the EU4, followed by the United Kingdom
  • Key Vasomotor Symptoms Companies: Mithra Pharmaceuticals, Bayer/Nerre Therapeutics, Astellas Pharma, MenoGeniX, Estetra, Mitsubishi Tanabe Pharma, QUE Oncology, Bayer, Duramed Research, Mitsubishi Tanabe Pharma, Pfizer, Fervent Pharma, Astellas Pharma, Merck Sharp & Dohme, Que Oncology, Eli Lilly and Company, and others
  • Key Vasomotor Symptoms Therapies: Donesta(E4, Estetrol), Elinzanetant (BAY-3427080, NT 814), Fezolinetant (ESN-364), MNGX-100 (Filgrastim, G-CSF), Elismetrep(MT-8554), Q-122 (MSX-122), Estetrol, Angeliq (Drospirenone/17ß-estradiol, BAY86-4891), SCE-B, MT-8554, desvenlafaxine succinate, DVS-233 SR, FP-101, Estradiol/DRSP, fezolinetant, esmirtazapine, Q-122, Raloxifene, and others
  • The Vasomotor Symptoms epidemiology based on age-specific cases analyzed that Vasomotor Symptoms is most prevalent in females at an age of 60–65 years old
  • The Vasomotor Symptoms market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Vasomotor Symptoms pipeline products will significantly revolutionize the Vasomotor Symptoms market dynamics.

 

Vasomotor Symptoms Overview

Vasomotor Symptoms (VMS), which mostly affect the head, neck, chest, and upper back, are episodes of intense heat accompanied by perspiration and flushing. Hot flashes and nocturnal sweats are frequent companions of vasomotor symptoms, which are frequently regarded as the primary signs of menopause.

 

Get a Free sample for the Vasomotor Symptoms Market Report 

https://www.delveinsight.com/report-store/vasomotor-symptoms-market

 

Vasomotor Symptoms Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Vasomotor Symptoms Epidemiology Segmentation:

The Vasomotor Symptoms market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Vasomotor Symptoms
  • Prevalent Cases of Vasomotor Symptoms by severity
  • Gender-specific Prevalence of Vasomotor Symptoms
  • Diagnosed Cases of Episodic and Chronic Vasomotor Symptoms

 

Download the report to understand which factors are driving Vasomotor Symptoms epidemiology trends @ Vasomotor Symptoms Epidemiology Forecast

 

Vasomotor Symptoms Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vasomotor Symptoms market or expected to get launched during the study period. The analysis covers Vasomotor Symptoms market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Vasomotor Symptoms Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Vasomotor Symptoms Therapies and Key Companies

  • Donesta(E4, Estetrol): Mithra Pharmaceuticals
  • Elinzanetant (BAY-3427080, NT 814): Bayer/Nerre Therapeutics
  • Fezolinetant (ESN-364): Astellas Pharma
  • MNGX-100 (Filgrastim, G-CSF): MenoGeniX
  • Elismetrep(MT-8554): Mitsubishi Tanabe Pharma
  • Q-122 (MSX-122): QUE Oncology
  • Estetrol: Estetra
  • Angeliq (Drospirenone/17ß-estradiol, BAY86-4891): Bayer
  • SCE-B: Duramed Research
  • MT-8554: Mitsubishi Tanabe Pharma
  • desvenlafaxine succinate: Pfizer
  • DVS-233 SR: Pfizer
  • FP-101: Fervent Pharma
  • Estradiol/DRSP: Bayer
  • fezolinetant: Astellas Pharma
  • esmirtazapine: Merck Sharp & Dohme
  • Q-122: Que Oncology
  • Raloxifene: Eli Lilly and Company

 

Discover more about therapies set to grab major Vasomotor Symptoms market share @ Vasomotor Symptoms Treatment Market

 

Vasomotor Symptoms Market Drivers

  • An increasing population of geriatric women and raising awareness about women’s hygiene, dietary habits, and stress indicators have shed light on hormonal imbalances among women

 

Vasomotor Symptoms Market Barriers

  • Favorable policies initiated by the government to improve women’s health and raise awareness are likely to propel the market and drive various Pharmaceutical companies to conduct R&D activities

 

Scope of the Vasomotor Symptoms Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Vasomotor Symptoms Companies: Mithra Pharmaceuticals, Bayer/Nerre Therapeutics, Astellas Pharma, MenoGeniX, Estetra, Mitsubishi Tanabe Pharma, QUE Oncology, Bayer, Duramed Research, Mitsubishi Tanabe Pharma, Pfizer, Fervent Pharma, Astellas Pharma, Merck Sharp & Dohme, Que Oncology, Eli Lilly and Company, and others
  • Key Vasomotor Symptoms Therapies: Donesta(E4, Estetrol), Elinzanetant (BAY-3427080, NT 814), Fezolinetant (ESN-364), MNGX-100 (Filgrastim, G-CSF), Elismetrep(MT-8554), Q-122 (MSX-122), Estetrol, Angeliq (Drospirenone/17ß-estradiol, BAY86-4891), SCE-B, MT-8554, desvenlafaxine succinate, DVS-233 SR, FP-101, Estradiol/DRSP, fezolinetant, esmirtazapine, Q-122, Raloxifene, and others
  • Vasomotor Symptoms Therapeutic Assessment: Vasomotor Symptoms current marketed and Vasomotor Symptoms emerging therapies
  • Vasomotor Symptoms Market Dynamics: Vasomotor Symptoms market drivers and Vasomotor Symptoms market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Vasomotor Symptoms Unmet Needs, KOL’s views, Analyst’s views, Vasomotor Symptoms Market Access and Reimbursement 

 

To know more about Vasomotor Symptoms companies working in the treatment market, visit @ Vasomotor Symptoms Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Vasomotor Symptoms Market Report Introduction

2. Executive Summary for Vasomotor Symptoms

3. SWOT analysis of Vasomotor Symptoms

4. Vasomotor Symptoms Patient Share (%) Overview at a Glance

5. Vasomotor Symptoms Market Overview at a Glance

6. Vasomotor Symptoms Disease Background and Overview

7. Vasomotor Symptoms Epidemiology and Patient Population

8. Country-Specific Patient Population of Vasomotor Symptoms 

9. Vasomotor Symptoms Current Treatment and Medical Practices

10. Vasomotor Symptoms Unmet Needs

11. Vasomotor Symptoms Emerging Therapies

12. Vasomotor Symptoms Market Outlook

13. Country-Wise Vasomotor Symptoms Market Analysis (2019–2032)

14. Vasomotor Symptoms Market Access and Reimbursement of Therapies

15. Vasomotor Symptoms Market Drivers

16. Vasomotor Symptoms Market Barriers

17.  Vasomotor Symptoms Appendix

18. Vasomotor Symptoms Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services